age-related maculopathy


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

maculopathy, age-related

A condition in which there are large whitish-yellow soft drusen in the macular area and hyperpigmentation or depigmentation of the retinal pigment epithelium associated with the drusen. Small hard drusen may also be present. It occurs most commonly in individuals over 50 years of age and represents the early stage of age-related macular degeneration. The risk of progression of this condition may be decreased by dietary supplements of vitamin C and E, antioxidants (carotenoids such as lutein and zeaxanthin) and minerals (zinc and cupric acid).
References in periodicals archive ?
Glynn et al., "Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy," American Journal of Epidemiology, vol.
A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Ophthalmic Genetics, 23(4), 209-223.
Location of lesions associated with age-related maculopathy over a 10-year period: the Beaver Dam Eye Study.
The presence of ARMD was determined using fundus photographs taken by a digital nonmydriatic fundus camera (TRC-NW6S, Topcon) and graded using the grading protocol of the International Age-related Maculopathy Epidemiological Study Group [10].
Patients with diagnosed choroidal and retinal neovascularisation such as PDR, diabetic macular oedema, central retinal vein occlusion, neovascular glaucoma myopic maculopathy, and age-related maculopathy (wet type) were included in the study.
The Beaver Dam Eye Study, based in Wisconsin, provided epidemiologic evidence of a significant relationship between extended exposure to the sun and the incidence of early age-related maculopathy (ARM), while a study of watermen in Chesapeake Bay found an increased incidence of severe AMD among those exposed to higher levels of blue and visible light over the previous 20 years.
Carotenoids in age-related maculopathy Italian study (CARIS): two-year results of a randomized study.
The goal of the Study on the Genetics of Age-Related Maculopathy (GARM II) is to determine how the combination of genetic, dietary, health, and exposure factors such as sunlight or smoking contributes to a person's risk of developing this condition.
If supplementation does help prevent or delay AMD, it is likely a small benefit, with confidence intervals compatible with a protective effect not exceeding 10% for preventing age-related maculopathy (ARM) and 25% for preventing AMD (i.e., advanced ARM).
The association with hearing loss also was found in two subgroups of patients who had cataracts or age-related maculopathy, the two leading causes of visual impairment in this population.